Article (Scientific journals)
Le medicament du mois. Combinaison en proportion fixe insuline basale degludec-liraglutide (Xultophy(R)).
Scheen, André; Mathieu, Chantal
2018In Revue Médicale de Liège, 73 (10), p. 526-532
Peer reviewed
 

Files


Full Text
rmlg xultophy 201810_09.pdf
Publisher postprint (660.02 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Basal insulin; Glucagon like peptide 1; Insulin degludec; Liraglutide; Type 2 diabetes
Abstract :
[en] Xultophy(R) (IDegLira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. Insulin degludec is characterized by an original mode of prolonged and continuous insulin diffusion after its subcutaneous injection. Thereby, it has a very long half-life, around 25 hours, and a better reproducibility from both a pharmacokinetic and pharmacodynamic point of view, with less hypoglycaemia, especially at night. Liraglutide is a well-known once-daily GLP-1 receptor agonist that showed a cardiovascular and renal protection in patients with type 2 diabetes at high cardiovascular risk. Both molecules exert complementary antihyperglycaemic effects, which allows a better glucose control, both in the fasting and postprandial states. IDegLira is more effective than another basal insulin regimen in reaching individualized glycated haemoglobin target, with a lower daily dose of insulin. It has a better tolerance profile, with a more favourable effect on body weight and less hypoglycaemia compared with a basal insulin and less gastrointestinal adverse effects when compared with liraglutide alone. Xultophy(R) is presented as a prefilled pen and is indicated in the management of type 2 diabetes not well controlled with basal insulin. The dose of IDegLira is progressively uptitrated, starting from 16 dose steps up to a maximum of 50 dose steps per day (corresponding to 50 IU insulin degludec and 1.8 mg liraglutide).
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Mathieu, Chantal
Language :
French
Title :
Le medicament du mois. Combinaison en proportion fixe insuline basale degludec-liraglutide (Xultophy(R)).
Alternative titles :
[en] Basal insulin degludec - liraglutide fixed ratio combination (Xultophy(R))
Publication date :
2018
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
73
Issue :
10
Pages :
526-532
Peer reviewed :
Peer reviewed
Available on ORBi :
since 03 December 2018

Statistics


Number of views
183 (2 by ULiège)
Number of downloads
128 (1 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
1

Bibliography


Similar publications



Contact ORBi